REVVITY, INC (RVTY) Spending and interest coverage
- R&D / revenue · 12 months: Value 7.41%; Formula and calculation Research and development expense / revenue. Period ending 2026-07-05..
- Stock-based compensation / revenue · 12 months: Value 0.84%; Formula and calculation Share-based compensation / revenue. Period ending 2026-07-05..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-07-05; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 7.41% | Research and development expense / revenue. Period ending 2026-07-05. $215.83M ÷ $2.91B × 100 ≈ 7.41% |
| Stock-based compensation / revenue · 12 months | 0.84% | Share-based compensation / revenue. Period ending 2026-07-05. $24.43M ÷ $2.91B × 100 ≈ 0.84% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 215.83M USD | Research and Development Expense |
| Revenue | 2.91B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 24.43M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 358.85M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-05 | $215.83M | $2.91B | $24.43M | $358.85M | (m) | 7.41% | 0.84% | (m) | (m) |
| 2026-04-05 | $220.13M | $2.90B | $23.83M | $360.29M | (m) | 7.58% | 0.82% | (m) | (m) |
| 2025-12-28 | $215.84M | $2.86B | $22.85M | $356.63M | (m) | 7.56% | 0.80% | (m) | (m) |
| 2025-09-28 | $206.87M | $2.81B | $31.97M | $363.64M | (m) | 7.35% | 1.14% | (m) | (m) |
| 2025-06-29 | $205.22M | $2.80B | $33.45M | $379.89M | (m) | 7.33% | 1.20% | (m) | (m) |
| 2025-03-30 | $200.08M | $2.77B | $33.85M | $374.86M | (m) | 7.22% | 1.22% | (m) | (m) |
| 2024-12-29 | $196.84M | $2.76B | $37.81M | $346.74M | (m) | 7.14% | 1.37% | (m) | (m) |
| 2024-09-29 | $197.23M | $2.72B | $39.94M | $305.15M | (m) | 7.25% | 1.47% | (m) | (m) |
| 2024-06-30 | $201.13M | $2.71B | $40.10M | $276.23M | (m) | 7.43% | 1.48% | (m) | (m) |
| 2024-03-31 | $210.25M | $2.73B | $43.21M | $268.56M | (m) | 7.71% | 1.59% | (m) | (m) |
| 2023-12-31 | $216.58M | $2.75B | $41.41M | $300.56M | (m) | 7.87% | 1.51% | (m) | (m) |
| 2023-10-01 | $221.52M | $2.80B | $45.97M | $360.87M | (m) | 7.92% | 1.64% | (m) | (m) |
| 2023-07-02 | $222.00M | $2.84B | $45.38M | $402.42M | (m) | 7.83% | 1.60% | (m) | (m) |
| 2023-04-02 | $220.78M | $3.02B | $46.97M | $556.86M | (m) | 7.30% | 1.55% | (m) | (m) |
| 2023-01-01 | $221.62M | $3.31B | $51.52M | $742.70M | (m) | 6.69% | 1.56% | (m) | (m) |
| 2022-10-02 | $302.30M | $4.84B | $55.84M | $979.00M | (m) | 6.25% | 1.15% | (m) | (m) |
| 2022-07-03 | $298.89M | $5.02B | $51.71M | $1.04B | (m) | 5.95% | 1.03% | (m) | (m) |
| 2022-04-03 | $291.36M | $5.02B | $42.88M | $1.12B | (m) | 5.81% | 0.85% | (m) | (m) |
| 2022-01-02 | $274.97M | $5.07B | $32.78M | $1.33B | (m) | 5.43% | 0.65% | (m) | (m) |
| 2021-10-03 | $251.47M | $5.06B | $28.31M | $1.53B | $86.81M | 4.97% | 0.56% | 17.65× | Reported |
| 2021-07-04 | $232.99M | $4.85B | $28.83M | $1.56B | $55.34M | 4.80% | 0.59% | 28.16× | Reported |
| 2021-04-04 | $216.69M | $4.44B | $31.23M | $1.40B | $50.17M | 4.88% | 0.70% | 27.94× | Reported |
| 2021-01-03 | $205.39M | $3.78B | $29.13M | $978.58M | $49.71M | 5.43% | 0.77% | 19.69× | Reported |
| 2020-10-04 | $196.20M | $3.23B | $26.18M | $606.58M | $51.73M | 6.07% | 0.81% | 11.73× | Reported |
| 2020-07-05 | $191.45M | $2.98B | $31.37M | $437.23M | $55.82M | 6.43% | 1.05% | 7.83× | Reported |
| 2020-04-05 | $190.27M | $2.89B | $28.47M | $353.32M | $61.44M | 6.59% | 0.99% | 5.75× | Reported |
| 2019-12-29 | $189.34M | $2.88B | $31.51M | $361.97M | $63.63M | 6.57% | 1.09% | 5.69× | Reported |
| 2019-09-29 | $193.67M | $2.83B | $30.60M | $339.41M | $65.44M | 6.83% | 1.08% | 5.19× | Reported |
| 2019-06-30 | $197.14M | $2.80B | $29.42M | $340.95M | $65.97M | 7.04% | 1.05% | 5.17× | Reported |
| 2019-03-31 | $195.99M | $2.78B | $29.53M | $337.28M | $65.18M | 7.04% | 1.06% | 5.17× | Reported |
| 2018-12-30 | $194.00M | $2.78B | $28.77M | $323.88M | $66.98M | 6.98% | 1.04% | 4.84× | Reported |
| 2018-09-30 | $179.70M | $2.66B | $32.52M | $310.97M | $62.17M | 6.75% | 1.22% | 5.00× | Reported |
| 2018-07-01 | $165.74M | $2.54B | $25.80M | $308.81M | $56.47M | 6.52% | 1.01% | 5.47× | Reported |
| 2018-04-01 | $152.10M | $2.39B | $25.83M | $294.93M | $50.73M | 6.37% | 1.08% | 5.81× | Reported |
| 2017-12-31 | $139.40M | $2.26B | $25.42M | $304.80M | $43.94M | 6.18% | 1.13% | 6.94× | Reported |
| 2017-10-01 | $134.66M | $2.18B | $19.89M | $287.82M | $43.26M | 6.17% | 0.91% | 6.65× | Reported |
| 2017-07-02 | $129.29M | $2.14B | $19.25M | $283.80M | $43.28M | 6.03% | 0.90% | 6.56× | Reported |
| 2017-04-02 | $127.59M | $2.13B | $18.24M | $274.07M | $42.55M | 5.99% | 0.86% | 6.44× | Reported |
| 2017-01-01 | $124.28M | $2.12B | $17.16M | $283.07M | $41.53M | 5.87% | 0.81% | 6.82× | Reported |
| 2016-10-02 | $132.00M | $2.27B | $19.05M | $305.91M | $40.21M | 5.82% | 0.84% | 7.61× | Reported |
| 2016-07-03 | $129.92M | $2.28B | $19.44M | $300.58M | $39.09M | 5.69% | 0.85% | 7.69× | Reported |
| 2016-04-03 | $127.59M | $2.27B | $17.68M | $297.52M | $38.45M | 5.61% | 0.78% | 7.74× | Reported |
| 2016-01-03 | $125.93M | $2.26B | $17.72M | $286.13M | $38.00M | 5.57% | 0.78% | 7.53× | Reported |
| 2015-10-04 | $126.86M | $2.26B | $15.18M | $231.98M | $37.63M | 5.61% | 0.67% | 6.17× | Reported |
| 2015-06-28 | $126.21M | $2.24B | $13.34M | $214.85M | $36.66M | 5.63% | 0.60% | 5.86× | Reported |
| 2015-03-29 | $123.88M | $2.23B | $13.94M | $216.36M | $36.44M | 5.55% | 0.62% | 5.94× | Reported |
| 2014-12-28 | $121.14M | $2.24B | $14.46M | $210.74M | $36.27M | 5.41% | 0.65% | 5.81× | Reported |
| 2014-09-28 | $123.39M | $2.23B | $14.40M | $262.75M | $41.82M | 5.53% | 0.65% | 6.28× | Reported |
| 2014-06-29 | $124.35M | $2.21B | $15.73M | $261.93M | $44.62M | 5.63% | 0.71% | 5.87× | Reported |
| 2014-03-30 | $128.29M | $2.19B | $14.15M | $232.27M | $47.45M | 5.85% | 0.65% | 4.90× | Reported |
| 2013-12-29 | $133.02M | $2.17B | $14.05M | $217.44M | $49.92M | 6.14% | 0.65% | 4.36× | Reported |
| 2013-09-29 | $133.86M | $2.15B | $17.10M | $101.92M | $46.96M | 6.24% | 0.80% | 2.17× | Reported |
| 2013-06-30 | $134.73M | $2.13B | $18.42M | $87.94M | $46.62M | 6.32% | 0.86% | 1.89× | Reported |
| 2013-03-31 | $134.19M | $2.11B | $19.97M | $98.06M | $46.04M | 6.36% | 0.95% | 2.13× | Reported |
| 2012-12-30 | $132.64M | $2.12B | $21.03M | $98.54M | $45.79M | 6.27% | 0.99% | 2.15× | Reported |
| 2012-09-30 | $130.60M | $2.08B | $21.41M | $103.53M | $46.34M | 6.27% | 1.03% | 2.23× | Reported |
| 2012-07-01 | $128.30M | $2.03B | $17.77M | $96.45M | $39.43M | 6.33% | 0.88% | 2.45× | Reported |
| 2012-04-01 | $122.26M | (m) | $17.90M | $86.08M | $32.30M | (m) | (m) | 2.66× | Reported |
| 2012-01-01 | $115.82M | $1.92B | $15.48M | $91.13M | $24.78M | 6.03% | 0.81% | 3.68× | Reported |
| 2011-10-02 | $110.33M | $1.85B | $11.49M | $159.36M | (m) | 5.96% | 0.62% | (m) | (m) |
| 2011-07-03 | $103.91M | $1.82B | $12.78M | $166.57M | (m) | 5.72% | 0.70% | (m) | (m) |
| 2011-04-03 | $98.67M | $1.76B | $12.15M | $162.32M | (m) | 5.61% | 0.69% | (m) | (m) |
| 2011-01-02 | $95.41M | $1.70B | $12.42M | $153.60M | (m) | 5.60% | 0.73% | (m) | (m) |
| 2010-10-03 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-07-04 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-04-04 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-01-03 | $90.78M | $1.55B | $13.99M | $121.92M | (m) | 5.85% | 0.90% | (m) | (m) |
| 2009-10-04 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-07-05 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-28 | $93.03M | $1.66B | $18.15M | $147.63M | (m) | 5.61% | 1.09% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avantor, Inc. (AVTR) | United States | $10.501B | -9.72 |
| BRUKER CORP (BRKR) | United States | $9.706B | -128.75 |
| METTLER TOLEDO INTERNATIONAL INC/ (MTD) | $30.436B | 30.62 | |
| Alamar Biosciences, Inc. (ALMR) | United States | $2.300B | |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |